Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888845 | 0.88 | ALDH1A1 (0.51) | METAP2ALDH1A1TLR2ACEHPGD | |
| SCHEMBL3592883 | 0.87 | ACE (0.47) | METAP2ALDH1A1ACEHPGDLMNA | |
| SCHEMBL3577967 | 0.85 | KIF11 (0.46) | METAP2ALDH1A1TLR2ACEHPGD | |
| SCHEMBL3577970 | 0.85 | KIF11 (0.46) | METAP2ALDH1A1TLR2ACEHPGD | |
| SCHEMBL7544294 | 0.83 | CTSC (0.51) | METAP2ACE | |
| SCHEMBL3503447 | 0.82 | GLO1 (0.53) | METAP2ALDH1A1ACEHPGDMAPT | |
| SCHEMBL11880817 | 0.82 | GLO1 (0.53) | METAP2ALDH1A1ACEHPGDMAPT | |
| SCHEMBL20629402 | 0.82 | METAP2 (0.49) | METAP2TLR2ACE | |
| SCHEMBL2311329 | 0.82 | ALPI (0.56) | L3MBTL1POLB | |
| SCHEMBL987883 | 0.82 | ALPI (0.56) | L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2308839-A1 | Fused heterocyclic compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | METAP2 815/4885ALDH1A1 372/4885TLR2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.